Discovery of Quinazolinone Derivatives as Potent PARP1 Inhibitors
Poly-(ADP-ribose) polymerase 1 (PARP1) is the most abundant and well-characterized member of PARP family and plays a significant role in DNA damage detection and repair. Cancer cells with homogeneous recombination deficiency (HRD) depend on PARP1 mediated DNA repair for survival, which makes PARP1 as a potential cancer treatment target. This patent highlights the synthesis and pharmaceutical composition of novel quinazolinone based PARP inhibitors for cancer treatment.
Authors
- Steven H. Liang (ORCID: https://orcid.org/0000-0003-1413-6315)
- Xin Zhou (ORCID: https://orcid.org/0000-0002-7444-462X)
Institutions
- Georgia Institute of Technology (US)
- Emory University (US)
- The Wallace H. Coulter Department of Biomedical Engineering (US)
Publication Details
- Journal
- ACS Medicinal Chemistry Letters
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1021/acsmedchemlett.5c00747
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00